Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 235-237

  Spizzo, Gilbert ^a   Mitterer, Manfred ^a   Gunsilius, Eberhard ^b  

^a FRANZ TAPPEINER HOSPITAL   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

cryoglobulin; multiple myeloma; vascular disease

Indexed keywords

AZATHIOPRINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CREATININE; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB;

ABDOMINAL AORTA ANEURYSM; ACROCYANOSIS; ADULT; AGED; AORTA RUPTURE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; DISEASE ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; KARYOTYPE 46,XY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN BIOPSY; VASCULITIS;

ADULT; AGED; BORONIC ACIDS; CRYOGLOBULINEMIA; HUMANS; MALE; PROTEASE INHIBITORS; PYRAZINES; SKIN DISEASES, VASCULAR; VASCULITIS;

EID: 77954325388     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08184.x     Document Type: Letter

References (10)

1. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5, 417 421.
2. Brouet, J.C., Clauvel, J.P., Danon, F., Klein, M. Seligmann, M. (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. American Journal of Medicine, 57, 775 788.
3. Cohen, S.J., Pittelkow, M.R. Su, W.P. (1991) Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. Journal of the American Academy of Dermatology, 25, 21 27.
4. Kern, J., Untergasser, G., Zenzmaier, C., Sarg, B., Gastl, G., Gunsilius, E. Steurer, M. (2009) GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood, 114, 3960 3967.
5. Lamprecht, P., Gause, A. Gross, W.L. (1999) Cryoglobulinemic vasculitis. Arthritis & Rheumatism, 42, 2507 2516.
6. Richardson, P.G., Hideshima, T. Anderson, K.C. (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control, 10, 361 369.
7. Roccaro, A.M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G. Anderson, K.C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66, 184 191.
8. Talamo, G., Claxton, D., Tricot, G., Fink, L. Zangari, M. (2008) Response to bortezomib in refractory type I cryoglobulinemia. American Journal of Hematology, 83, 883 884.
9. Teicher, B.A., Ara, G., Herbst, R., Palombella, V.J. Adams, J. (1999) The proteasome inhibitor PS-341 in cancer therapy. Clinical Cancer Research, 5, 2638 2645.
10. Williams, S., Pettaway, C., Song, R., Papandreou, C., Logothetis, C. McConkey, D.J. (2003) Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Molecular Cancer Therapeutics, 2, 835 843.